Research Compounds

Body Protection Compound-157. One of the most studied peptides for tissue repair, gut health, and joint recovery.

Thymosin Beta-4 fragment known for promoting systemic healing, reducing inflammation, and supporting muscle repair.

Tripeptide (Lys-Pro-Val) representing the C-terminal fragment of alpha-MSH. Studied for anti-inflammatory and gut-lining research, independent of alpha-MSH's pigmentation and appetite effects.

GLP-1 receptor agonist widely studied for appetite regulation, blood sugar control, and body composition.

Dual GIP/GLP-1 receptor agonist studied for synergistic effects on insulin secretion, fat metabolism, and appetite suppression — showing a greater magnitude of weight loss than semaglutide in head-to-head trials.

Triple receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials recorded up to 24.2% body weight reduction — the highest of any compound in its class.

Long-acting amylin analog studied for appetite suppression and satiety signaling. Most researched in combination with semaglutide (as CagriSema), where Phase 3 data showed greater weight reduction than either compound alone.

Synthetic GHRH analog that stimulates endogenous growth hormone release. Studied for visceral fat reduction, body composition, and metabolic health.

Synthetic fragment of human growth hormone (hGH 176-191) studied for its role in fat metabolism and lipolysis without affecting blood sugar or IGF-1 levels.

A synergistic blend of growth hormone releasing hormone analog and growth hormone secretagogue for optimized GH pulses.

Growth hormone releasing hormone analogue that stimulates the pituitary to naturally increase GH production.

Long-acting analog of insulin-like growth factor 1 with extended half-life. Studied for muscle protein synthesis, lean tissue growth, and recovery — a common pairing with CJC-1295 / Ipamorelin stacks.

The foundational blend research stack: Body Protection Compound-157 paired with Thymosin Beta-4 in a single vial, pairing localized tissue-repair research with systemic healing research. The base every other blend on this page builds on.

The Wolverine Stack plus GHK-Cu in one vial — extending tissue-repair research into collagen synthesis, gene-expression, and dermal/follicular pathways alongside the same BPC-157 and TB-500 foundation.

The GLOW Stack plus KPV — a four-peptide blend extending the same tissue-repair and collagen research into anti-inflammatory and gut-lining pathways in a single reconstitution.

A co-formulated metabolic research blend pairing retatrutide — an investigational triple GIP/GLP-1/glucagon receptor agonist — with cagrilintide, a long-acting amylin analog, in a single vial (12.5 mg / 2.5 mg). Studied for overlapping incretin and amylin signaling pathways. Both compounds are investigational and unapproved; provided strictly as a chemical reagent for laboratory research use only.

A co-formulated metabolic research blend pairing cagrilintide — a long-acting amylin analog — with semaglutide, a GLP-1 receptor agonist, in a single vial. The dual amylin-plus-GLP-1 approach was studied in Novo Nordisk's Phase 3 REDEFINE program, where the combination produced greater weight reduction than either component alone. Semaglutide is FDA-approved only as a specific finished drug; the bulk peptide and this combination are unapproved and provided strictly as a chemical reagent for laboratory research use only.

Melanocortin receptor agonist studied for its role in libido and sexual health in both men and women.

Mitochondria-targeted tetrapeptide that binds directly to cardiolipin in the inner mitochondrial membrane, stabilizing membrane structure and reducing oxidative stress at the site of energy production.

Synthetic pan-agonist of the estrogen-related receptor family (ERRα/β/γ) developed at Saint Louis University, studied for activating exercise-associated transcriptional programs — mitochondrial biogenesis, fatty-acid oxidation, and oxidative metabolism — without physical exertion.

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) studied for its role in telomerase activation, cellular longevity, and regulation of the pineal gland's melatonin output.

Mitochondrial-derived peptide that regulates metabolic homeostasis, improves insulin sensitivity, and supports cellular energy production. Active in clinical trials for metabolic disease.

Naturally occurring copper-binding tripeptide (Gly-His-Lys) studied for skin regeneration, wound healing, hair follicle stimulation, and collagen synthesis. Declines naturally with age.

Coenzyme central to mitochondrial energy production, DNA repair, and cellular longevity. Levels decline with age; supplementation is studied for metabolic health, cognitive function, and healthspan.

Nonapeptide first isolated from rabbit cerebral venous blood in the 1970s, studied for slow-wave sleep promotion, stress-axis modulation, and opioid-withdrawal research — despite decades of study, its receptor and precursor gene remain unidentified.

The body's master antioxidant — a tripeptide of glutamate, cysteine, and glycine that neutralizes reactive oxygen species, recycles vitamins C and E, and drives phase-II liver detoxification. Studied for oxidative-stress modulation, hepatic function, and as a research reference for cellular redox balance.